Abstract
The antineoplastic drug doxorubicin is known to cause cytopenias. In humans and in dogs treated with doxorubicin, neutropenia is a common haematological toxicity. To determine the mechanism of doxorubicin haematotoxicity in the dog, in vitro bone marrow progenitor and microenvironment assays were done in the presence of doxorubicin. The 50% inhibitory concentration (IC50) of doxorubicin for canine erythroid colony-forming unit (CFU-E) was 0.042 ± 0.01 μM and for canine granulocyte-macrophage colony-forming unit (CFU-GM) it was 0.0084 ± 0.002 μM To determine the effects of doxorubicin on the bone marrow microenvironment, fibroblast colony-forming unit (CFU-F) assays were performed. The 50% inhibitory concentration for canine CFU-F was 0.030 ± 0.01 μM. Morphologically, the CFU-F were made up of predominantly cells (73 ± 8%) with fibroblast-like morphology. Within the colonies as well as between the colonies, there were cells with macrophage (27 ± 8%) morphology. To support the morphological classification of these cells, cytochemical staining was done. The cells with the fibroblast-like morphology were negative for butyrate esterase and those with macrophage morphology were positive, whereas both cell types were positive for acid phosphatase in the presence or absence of tartrate. Our data show that the effects of doxorubicin on in vitro haematopoiesis in the dog are similar to those described in man.
Similar content being viewed by others
References
Aghai E, Tokes ZA (1990) Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells. Cancer Chemother Pharmacol 25:295–298
Bailey-Wood R, Dallimore CM, Whittaker JA (1984) Effect of adriamycin on CFU-GM at plasma concentrations found following therapeutic infusion. Br J Cancer 50:351–355
Benjamin RS, Wiernik PH, Bachur NR (1974) Adriamycin chemotherapy: efficacy, safety, and pharmacology basis of an intermittent single high-dosage schedule. Cancer 33:19–27
Blum RH, Carter SK (1974) Adriamycin: a new anthracycline drug with significant clinical activity. Ann Intern Med 80:249–259
Bonadonna G, Monfardini S, DeLena M, Fossati-Bellani F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin. Cancer Res 30:2572–2582
Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM (1989) The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 60:121–125
Broudy VC, Zucherman KS, Jetmalani S, Fitchen JH, Grover C, Bagby J (1986) Monocytes stimulate fibroblastoid bone marrow stromal cells to produce multilineage hematopoietic growth factors. Blood 68:530–534
Busch FW, Schmittele U, Ehninger G (1990) Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil. Blut 60:219–222
Carter RF, Harris CK, Withrow SJ, Vali VEO, Susaneck SJ (1987) Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 23:587–596
Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P et al. (1980) Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 56:289–301
Chabner BA, Myers CE (1989) Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. J. B. Lippincott, Philadelphia, PA, pp 349–395
Charbord P, Tamayo E, Saeland S, Duvert V, Poulet J, Gown AM et al. (1991) Granuloctye-macrophage colony-stimulating factor (GM-CSF) in human long-term bone marrow cultures: endogeneous production in the adherent layer and effect of exogeneous GM-CSF on granulomonopoiesis. Blood 78:1230–1236
Deldar A, Lewis H, Bloom J, Weiss L (1988) Reproducible cloning assays for in vitro growth of canine hematopoietic progenitor cells and their potential applications in investigative hematotoxicity. Am J Vet Res 49:1393–1401
Dessypris EN, Brenner DE, Hande KR (1986) Toxicity of doxorubicin metabolites to human erythroid and myeloid progenitors in vitro. Cancer Treat Rep 70:487–490
Gaunt SD, Pierce KR (1986) Effects of estradiol on hematopoietic and marrow adherent cells of dogs. Am J Vet Res 47:906–909
Gralla EJ, Fleischman RW, Luthra YK, Standnicki SW (1979) The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkeys. Toxicology 13:263–273
Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 66:1139–1143
Klinnert V, Nothdurft W, Fliedner TM (1985) CFU-F from dog marrow: a colony assay and its significance. Blut 50:81–87
Migliaccio AR, Migliaccio G, Johnson G, Adamson JW, Torok-Storb B (1990) Comparative analysis of hematopoietic growth factors released by stromal cells from normal donors or transplanted patients. Blood 75:305–312
Myers CE, Mimnaugh EG, Yeh GC, Sinha BK (1988) Biochemical mechanisms of tumor cell kill by the anthracyclines. In: Lown JW (ed) Anthracycline and anthracenedione-based anti-cancer agents. Elsevier, New York, pp 527–569
Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA et al. (1989a) Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 195:1580–1587
Ogilvie GK, Richardson RC, Curtis CR, Withrow SJ, H. A. Reynolds V, Norris AM et al. (1989b) Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 195:1584–1587
Ogilvie GK, Vail DM, Klein MK, Powers B, Dickinson K (1991) Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 198:1762–1764
Postorino NC, Susaneck SJ, Withrow SJ, Macy DW, Harris C (1989) Single agent therapy with adriamycin for canine lymphosarcoma. J Am Anim Hosp Assoc 25:221–225
Smith DM, Kirk GR (1976) Some systemic effects of adriamycin on the dog. J Am Anim Hosp Assoc 12:92–97
Spurling NW (1977) Haematology of the dog. In: Archer RK, Jeffcott LB (eds) Comparative clinical haematololgy. Blackwell Scientific Publications, Oxford, pp 365–440
Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468
Van Der Graaf WTA, De Vries EGE, Uges DRA, Nanninga AG, Meijer C, Vellenga et al. (1991) In vitro and in vivo modulation of multi-drug resistance with amiodarone. Int J Cancer 48:616–622
Wilson FD, Tavassoli M, Greenberg BR, Hinds D, Klein AK (1981) Morphological studies on ‘adherent cells’ in bone marrow cultures from humans, dogs, and mice. Stem Cells 1:15–29
Young RC, Ozois RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139–153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reagan, W.J., Handy, V., McKamey, A. et al. Effects of doxorubicin on the canine erythroid and myeloid progenitor cells and bone marrow microenvironment. Comp Haematol Int 3, 96–101 (1993). https://doi.org/10.1007/BF00368112
Issue Date:
DOI: https://doi.org/10.1007/BF00368112